ArticleFrontiers in oncology2025
Ga-68 DOTATATE PET imaging in the management of head and neck paragangliomas: a potential game changer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck paragangliomas (HNPGs) are rare neuroendocrine tumors originating from neural crest cells, with some exhibiting malignant potential. Traditional imaging modalities, such as magnetic resonance imaging (MRI), often have limitations in detecting multifocal or metastatic disease, driving interest in more sensitive diagnostic approaches like Gallium-68 DOTATATE positron emission tomography/computed tomography (Ga-68 DOTATATE PET/CT). Methods: This retrospective study aimed to assess the effectiveness of Ga-68 DOTATATE PET/CT in the detection and management of HNPGs. Imaging data from 2015 to 2024 were reviewed, identifying four confirmed cases of HNPG. All patients underwent head and neck MRI and Ga-68 DOTATATE PET/CT scans. Data on imaging findings, treatment history, and clinical outcomes were collected and analyzed to compare the performance of Ga-68 DOTATATE PET/CT with other imaging techniques, including Iodine-123 meta-iodobenzylguanidine (I-123 MIBG) scintigraphy and Fluorine-18 fluorodeoxyglucose (F-18 FDG) PET/CT. Results: Ga-68 DOTATATE PET/CT demonstrated enhanced sensitivity in detecting both primary and metastatic lesions compared to MRI and other imaging modalities. It identified additional lesions not seen on MRI, confirmed local recurrence, and detected unsuspected metastatic sites, influencing clinical management. While Ga-68 DOTATATE PET/CT provided more diagnostic clarity than I-123 MIBG in one case, it also revealed additional metastatic sites in a patient with a succinate dehydrogenase (SDH) gene mutation, which were not detected by F-18 FDG PET/CT. Conclusion: Ga-68 DOTATATE PET/CT is a valuable imaging tool for evaluating HNPGs, with superior sensitivity in detecting both primary and metastatic lesions compared to conventional imaging. Its diagnostic advantages can significantly impact treatment planning and patient management. Integrating Ga-68 DOTATATE PET/CT into clinical guidelines for HNPG evaluation may enhance diagnostic accuracy. Further research with larger cohorts is warranted to confirm these findings and establish standardized interpretation criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.